Corbus reports Q4 net loss $9.5M, cash $149.1M; pipeline updates on CRB-701, CRB-913, CRB-601

Corbus Pharmaceuticals Holdings, Inc.

Net loss Q4 2024 $9.5M ($0.78/share) vs $8.0M ($1.81/share) in Q4 2023; full-year loss $40.2M ($3.68/share).
Cash and investments $149.1M at Dec 31, 2024; expected to fund operations through Q3 2027.
CRB-701 (Nectin-4 ADC) Phase 1 shows safety and responses in HNSCC, cervical, and mUC; FDA Fast Track for metastatic cervical cancer.
CRB-913 obesity Ph1 SAD/MAD first dosing expected March 2025; CRB-601 first patient dosed Dec 2024, dose escalation Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.